Glenmark Pharma launches lung cancer treatment drug in India; shares up 2%

Glenmark Pharmaceuticals on Tuesday, June 24, announced the launch of its lung cancer treatment drug Tevimbra in India, after receiving approval from the Central Drugs Standard Control Organisation.

Tevimbra, developed by BeiGene (now BeOne Medicines), marks the pharmaceutical’s first foray into the immune-oncology space in India. Furthermore, it is a major milestone expanding its oncology portfolio, Glenmark Pharma said in a regulatory filing.

Commenting on the launch, Alok Malik, Glenmark Pharmaceutical’s Presidet and Business Head of India Formulations, said: "At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact."

Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients".

Tevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophageal squamous cell carcinoma (ESCC) as monotherapy, the company said.

The drug has also been approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China.

Glenmark shares closed in the green at ₹1,686 apiece, up 0.07% on the National Stock Exchange (NSE) on Tuesday, following the announcement of the cancer drug launch. The drug maker’s stock surged 1.12% to an intra-day high of ₹1,703.70 apiece during the trading session.

The scrip lost 1.99% over the previous week but gained 15.51% since the beginning of June. It has soared 6.4% so far in the first quarter of FY26 and 4.6% year-to-date.

Glenmark Pharmaceuticals has a total market capitalisation of ₹47,579.06 crore, as of June 24, 2025, according to the data on the NSE.